Your browser doesn't support javascript.
loading
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
Stahler, Arndt; Heinemann, Volker; Schuster, Veronika; Heinrich, Kathrin; Kurreck, Annika; Gießen-Jung, Clemens; Fischer von Weikersthal, Ludwig; Kaiser, Florian; Decker, Thomas; Held, Swantje; Graeven, Ullrich; Schwaner, Ingo; Denzlinger, Claudio; Schenk, Michael; Neumann, Jens; Kirchner, Thomas; Jung, Andreas; Kumbrink, Jörg; Stintzing, Sebastian; Modest, Dominik P.
Afiliação
  • Stahler A; Charité Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumour Immunology, Charitéplatz 1, 10117, Berlin, Germany. Electronic address: arndt.stahler@charite.de.
  • Heinemann V; Department of Medicine III, University Hospital, LMU, Munich, Germany; LMU Munich, German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schuster V; Department of Medicine III, University Hospital, LMU, Munich, Germany.
  • Heinrich K; Department of Medicine III, University Hospital, LMU, Munich, Germany.
  • Kurreck A; Charité Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumour Immunology, Charitéplatz 1, 10117, Berlin, Germany.
  • Gießen-Jung C; Department of Medicine III, University Hospital, LMU, Munich, Germany.
  • Fischer von Weikersthal L; Klinikum St. Marien, Oncology, Amberg, Germany.
  • Kaiser F; Onkologische Praxis, Landshut, Germany.
  • Decker T; Onkologische Praxis, Ravensburg, Germany.
  • Held S; ClinAssess GmbH, Leverkusen, Germany.
  • Graeven U; Department of Hematology, Oncology and Gastroenterology, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.
  • Schwaner I; Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany.
  • Denzlinger C; Marienhospital, Stuttgart, Germany.
  • Schenk M; Krankenhaus Barmherzige Brüder Regensburg, Regensburg, Germany.
  • Neumann J; Institute of Pathology, University of Munich, Germany.
  • Kirchner T; LMU Munich, German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology, University of Munich, Germany.
  • Jung A; LMU Munich, German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology, University of Munich, Germany.
  • Kumbrink J; LMU Munich, German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Pathology, University of Munich, Germany.
  • Stintzing S; Charité Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumour Immunology, Charitéplatz 1, 10117, Berlin, Germany; Charité - Universitätsmedizin, German Cancer Consortium (DKTK), Partner Site Berlin, German
  • Modest DP; Charité Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumour Immunology, Charitéplatz 1, 10117, Berlin, Germany; Charité - Universitätsmedizin, German Cancer Consortium (DKTK), Partner Site Berlin, German
Eur J Cancer ; 157: 71-80, 2021 11.
Article em En | MEDLINE | ID: mdl-34507244
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica Idioma: En Ano de publicação: 2021 Tipo de documento: Article